These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25848336)

  • 21. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
    Malenfant SJ; Eckmann KR; Barnett CM
    Pharmacotherapy; 2014 Jan; 34(1):60-71. PubMed ID: 23918291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
    Zardavas D; Bozovic-Spasojevic I; de Azambuja E
    Curr Opin Oncol; 2012 Nov; 24(6):612-22. PubMed ID: 23014186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual HER2-targeted approaches in HER2-positive breast cancer.
    Ahn ER; Vogel CL
    Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
    Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
    Yu Q; Zhu Z; Liu Y; Zhang J; Li K
    PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in novel targeted therapies for HER2-positive breast cancer.
    Murphy CG; Morris PG
    Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
    Zelnak AB; Wisinski KB
    Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer.
    Cao Y; Li Y; Liu R; Zhou J; Wang K
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature.
    Ge JY; Overmoyer B
    Case Rep Oncol; 2021; 14(2):1071-1079. PubMed ID: 34326744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The changing treatment of metastatic her2-positive breast cancer.
    Mitsogianni M; Trontzas IP; Gomatou G; Ioannou S; Syrigos NK; Kotteas EA
    Oncol Lett; 2021 Apr; 21(4):287. PubMed ID: 33732363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review.
    Chan WL; Lam TC; Lam KO; Luk MY; Kai-Cheong RN; Kwong LD
    Ther Adv Med Oncol; 2020; 12():1758835920953729. PubMed ID: 32973930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series.
    Takuwa H; Tsuji W; Yotsumoto F
    Int J Surg Case Rep; 2018; 52():125-131. PubMed ID: 30343261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
    Schneeweiss A; Ruckhäberle E; Huober J
    Geburtshilfe Frauenheilkd; 2015 Jun; 75(6):574-583. PubMed ID: 26166838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a role for immunotherapy in HER2-positive breast cancer?
    Holgado E; Perez-Garcia J; Gion M; Cortes J
    NPJ Breast Cancer; 2018; 4():21. PubMed ID: 30131972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.